Tutti gli studi
ReclutamentoFASE1, FASE2INTERVENTISTICO

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

This study looks at a new targeted medicine called repotrectinib for children, teenagers, and young adults up to 25 years old. It is designed for people with advanced solid tumours, brain tumours, or lymphomas that carry specific faulty genes called ROS1 or NTRK. These gene faults act like broken switches, telling cancer cells to keep growing. The trial has two main parts. The first part works out the safest and most comfortable dose for children under 12. The second part tests how well the drug shrinks tumours in people aged 12 to 25, as well as younger children once their best dose is confirmed. Repotrectinib is taken by mouth as a pill or liquid. Taking part involves taking the medicine every day, coming to regular hospital check-ups, and having scans to see if the treatment is helping.

A colpo d'occhio

Stato
Reclutamento
Fase
FASE1, FASE2
Sponsor
Turning Point Therapeutics, Inc.
Obiettivo di iscrizione
75
Inizio
12 Mar 2020
Completamento stimato
30 Set 2027

Di cosa tratta questo studio?

Some cancers are driven by specific changes in their genetic code. In this trial, researchers are focusing on changes involving genes called ROS1, NTRK, and ALK. When these genes fuse with other genes, they can make cancer cells grow and spread quickly. Repotrectinib is a type of targeted therapy designed to block the signals these faulty genes produce, aiming to slow down or stop the cancer from growing.

Because this is an early-stage study, doctors are carrying it out in two phases. Phase 1 focuses on younger children under 12 years old. Its goal is to find the right dose that works against the tumour without causing too many uncomfortable side effects. Phase 2 includes teenagers and young adults aged 12 to 25 (and later, younger children), looking closely at whether the medicine actually shrinks tumours or keeps them stable.

This trial matters because children and young people with advanced or recurring cancers often have very limited treatment choices. Finding targeted medicines that can be taken by mouth could offer a kinder and more effective option when standard therapies such as chemotherapy or radiotherapy have stopped working.

Punti chiave

  • Tests a targeted oral medicine called repotrectinib for children and young adults aged 0 to 25.
  • Aimed at advanced solid tumours, brain tumours, or lymphomas with ROS1 or NTRK gene changes.
  • Designed for patients who have already tried standard treatments or have no other curative options.
  • The study checks the safest dose for young children and measures how well the drug shrinks tumours.
  • Taking part is voluntary, and you can withdraw at any time without losing standard medical support.

Chi può essere idoneo?

This study is open to children, teenagers, and young adults up to the age of 25 who have an advanced solid tumour, a primary brain tumour, or a type of lymphoma. To be considered, testing on a tumour sample must show a confirmed change in the ROS1 or NTRK genes. It is meant for patients whose cancer has continued to grow after standard treatments, or for whom no standard curative therapy exists.

Participants must have tumour areas that can be measured on scans so doctors can monitor any changes. It is also important that patients are reasonably active (able to be out of bed for at least half the day) and have working liver, kidney, and bone marrow function. If someone has a brain tumour, their condition must be stable.

You cannot join this study if your cancer is neuroblastoma that is only present in the bone marrow, or if you are still recovering from severe side effects caused by recent cancer treatments.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. The patient is aged 25 or younger.
  2. The patient has an advanced solid tumour, brain tumour, or lymphoma.
  3. A lab test has confirmed a ROS1 or NTRK gene change in the tumour.
  4. The tumour can be measured on a CT or MRI scan.
  5. The patient is well enough to be up and about for at least half of the day.
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you or your child join this study, the trial medicine (repotrectinib) will be taken by mouth as capsules or a liquid once or twice every day. You can take this medicine at home, but you will need to keep a simple diary to record each dose.

You will need to visit the hospital regularly, especially during the first few weeks, so the medical team can keep a close eye on your health. These visits will include physical examinations, blood tests, heart checks (such as ECGs), and regular imaging scans (like MRI or CT scans) to check on the tumour.

Participants can usually remain on the study for as long as the medicine helps to control the cancer without causing unacceptable side effects. Taking part is entirely voluntary, and you can decide to stop the treatment at any time.

Rischi e benefici potenziali

The main hope of this study is that repotrectinib will shrink the cancer or stop it from growing, but this cannot be guaranteed. The information gathered will also help doctors care for other young people with similar cancers in the future. However, new medicines always carry risks. Repotrectinib can cause side effects such as tiredness, dizziness, changes in taste, tingling sensations, or changes in blood test results. Your medical team will monitor you closely and can adjust the dose or pause treatment if needed. You are always free to leave the trial at any point without it affecting your standard NHS care.

Locations (68)

  • Ospedale Pediatrico di Los Angeles
    Codice postale verificato
    Los Angeles, Stati Uniti· Reclutamento
  • University of California at Los Angeles
    Codice postale verificato
    Los Angeles, Stati Uniti· Reclutamento
  • Children's Hospital Colorado - Anschutz Medical Campus
    Codice postale verificato
    Aurora, Stati Uniti· Reclutamento
  • Local Institution - 2105
    Codice postale verificato
    Orlando, Stati Uniti· Completato
  • Local Institution - 2120
    Codice postale verificato
    Orlando, Stati Uniti· Completato
  • Children's Healthcare of Atlanta - Egleston Hospital
    Codice postale verificato
    Atlanta, Stati Uniti· Reclutamento
  • Maine Medical Center
    Codice postale verificato
    Scarborough, United States· Reclutamento
  • Dana Farber Cancer Institute.
    Codice postale verificato
    Boston, Stati Uniti· Reclutamento
  • Washington University School of Medicine in St. Louis
    Codice postale verificato
    St Louis, Stati Uniti· Reclutamento
  • Local Institution - 2110
    Codice postale verificato
    New Brunswick, United States· Completato
  • Local Institution - 2102
    Codice postale verificato
    New York, Stati Uniti· Completato
  • Levine Children's Hospital- Pediatric Neuro-Oncology
    Codice postale verificato
    Charlotte, Stati Uniti· Reclutamento

Domande comuni

How is the trial medicine given?

Repotrectinib is taken by mouth as a pill or a liquid, meaning it can be taken at home rather than requiring an intravenous drip in the hospital.

How do I know if my tumour has the right gene change?

Your hospital team can test a small sample of tumour tissue that was removed during a previous biopsy or operation to see if it carries the ROS1 or NTRK gene changes.

Will taking part cost anything?

No. The study drug and any extra tests required by the clinical trial are provided free of charge. Some trials also help with travel expenses to and from the hospital.

Can I leave the trial if I change my mind?

Yes. You can leave the study at any time and for any reason. Your normal medical care and relationship with your doctors will not be affected.

What happens if the cancer continues to grow?

If scans show that the tumour is growing or if the treatment is causing difficult side effects, your doctor will discuss stopping the trial drug and looking at other care options.

Come saperne di più

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "A Study of Repotrectinib in Pediatric and Young Adult Subjec…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.